1. Home
  2. KNSA vs KMT Comparison

KNSA vs KMT Comparison

Compare KNSA & KMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • KMT
  • Stock Information
  • Founded
  • KNSA 2015
  • KMT 1938
  • Country
  • KNSA United Kingdom
  • KMT United States
  • Employees
  • KNSA N/A
  • KMT N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • KMT Industrial Machinery/Components
  • Sector
  • KNSA Health Care
  • KMT Industrials
  • Exchange
  • KNSA Nasdaq
  • KMT Nasdaq
  • Market Cap
  • KNSA 1.7B
  • KMT 2.0B
  • IPO Year
  • KNSA 2018
  • KMT N/A
  • Fundamental
  • Price
  • KNSA $21.09
  • KMT $29.02
  • Analyst Decision
  • KNSA Strong Buy
  • KMT Hold
  • Analyst Count
  • KNSA 5
  • KMT 5
  • Target Price
  • KNSA $36.60
  • KMT $25.00
  • AVG Volume (30 Days)
  • KNSA 365.7K
  • KMT 1.1M
  • Earning Date
  • KNSA 10-29-2024
  • KMT 11-06-2024
  • Dividend Yield
  • KNSA N/A
  • KMT 2.76%
  • EPS Growth
  • KNSA N/A
  • KMT N/A
  • EPS
  • KNSA N/A
  • KMT 1.28
  • Revenue
  • KNSA $384,098,000.00
  • KMT $2,036,371,000.00
  • Revenue This Year
  • KNSA $60.05
  • KMT $0.59
  • Revenue Next Year
  • KNSA $36.32
  • KMT $2.57
  • P/E Ratio
  • KNSA N/A
  • KMT $22.52
  • Revenue Growth
  • KNSA 54.41
  • KMT N/A
  • 52 Week Low
  • KNSA $15.52
  • KMT $22.50
  • 52 Week High
  • KNSA $28.15
  • KMT $32.18
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 34.36
  • KMT 56.47
  • Support Level
  • KNSA $20.41
  • KMT $27.63
  • Resistance Level
  • KNSA $21.55
  • KMT $30.36
  • Average True Range (ATR)
  • KNSA 0.87
  • KMT 1.05
  • MACD
  • KNSA -0.14
  • KMT -0.09
  • Stochastic Oscillator
  • KNSA 21.90
  • KMT 44.44

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About KMT Kennametal Inc.

Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.

Share on Social Networks: